MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0026-895X/04/6502-426-436$20.00
Mol Pharmacol 65:426-436, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correction
Right arrow An erratum has been published
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Waldo, G. L.
Right arrow Articles by Harden, T. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Waldo, G. L.
Right arrow Articles by Harden, T. K.

Agonist Binding and Gq-Stimulating Activities of the Purified Human P2Y1 Receptor

Gary L. Waldo, and T. Kendall Harden

Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina

The human P2Y1 receptor (P2Y1-R) was purified after high-level expression from a recombinant baculovirus in Sf9 insect cells. Quantification by protein staining and with a radioligand binding assay using the high-affinity P2Y1-R antagonist [3H]MRS2279 ([3H]2-chloro-N6-methyl-(N)-methanocarba-2'-deoxyadenosine 3',5'-bis-phosphate) indicated a nearly homogenous preparation of receptor protein. Ki values determined in [3H]MRS2279 binding assays for antagonists with the purified P2Y1-R were in good agreement with the Ki and KB values determined for these molecules in membrane binding and activity assays, respectively. Availability of P2Y1-R in purified form allowed direct determination of nucleotide agonist affinities under conditions not compromised by nucleotide metabolism/interconversion, and an order of affinities of 2-methylthio-ADP (2MeSADP) > ADP = 2-methylthioATP = adenosine-5'-O-(3-thio)triphosphate = adenosine-5'-O(2-thiodiphosphate) >> ATP was obtained. The signaling activity of the purified P2Y1-R was quantified after reconstitution in proteoliposomes with heterotrimeric G proteins. Steady-state GTP hydrolysis in vesicles reconstituted with P2Y1-R and G{alpha}q{beta}1{gamma}2 was stimulated by the addition of either 2MeADP or RGS4 alone and was increased by up to 50-fold in their combined presence. EC50 values of agonists for activation of the purified P2Y1-R were similar to their respective Ki values determined in radioligand binding experiments with the purified receptor. Moreover, ATP exhibited 20-fold higher EC50 and Ki values than did ADP and was a partial agonist relative to ADP and 2MeSADP under conditions in which no metabolism of the nucleotide occurred. Both RGS4 and PLC-{beta}1 were potent and efficacious GTPase-activating proteins for G{alpha}q and G{alpha}11 in P2Y1-R–containing vesicles. These results illustrate that the binding and signaling properties of the human P2Y1-R can be studied with purified proteins under conditions that circumvent the complications that occur in vivo.


Received September 3, 2003; accepted November 5, 2003

Address correspondence to: Dr. T. Kendall Harden, Department of Pharmacology, CB#7365, University of North Carolina, Chapel Hill, Chapel Hill, NC 27599-7365. E-mail: tkh{at}med.unc.edu




This article has been cited by other articles:


Home page
BloodHome page
J. E. Purvis, M. S. Chatterjee, L. F. Brass, and S. L. Diamond
A molecular signaling model of platelet phosphoinositide and calcium regulation during homeostasis and P2Y1 activation
Blood, November 15, 2008; 112(10): 4069 - 4079.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
S. J. Rayment, V. Ralevic, D. A. Barrett, R. Cordell, and S. P. H. Alexander
A novel mechanism of vasoregulation: ADP-induced relaxation of the porcine isolated coronary artery is mediated via adenosine release
FASEB J, February 1, 2007; 21(2): 577 - 585.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
M. P. Abbracchio, G. Burnstock, J.-M. Boeynaems, E. A. Barnard, J. L. Boyer, C. Kennedy, G. E. Knight, M. Fumagalli, C. Gachet, K. A. Jacobson, et al.
International Union of Pharmacology LVIII: Update on the P2Y G Protein-Coupled Nucleotide Receptors: From Molecular Mechanisms and Pathophysiology to Therapy
Pharmacol. Rev., September 1, 2006; 58(3): 281 - 341.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. Alvarado-Castillo, T. K. Harden, and J. L. Boyer
Regulation of P2Y1 Receptor-Mediated Signaling by the Ectonucleoside Triphosphate Diphosphohydrolase Isozymes NTPDase1 and NTPDase2
Mol. Pharmacol., January 1, 2005; 67(1): 114 - 122.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. Chhatriwala, R. G. Ravi, R. I. Patel, J. L. Boyer, K. A. Jacobson, and T. K. Harden
Induction of Novel Agonist Selectivity for the ADP-Activated P2Y1 Receptor Versus the ADP-Activated P2Y12 and P2Y13 Receptors by Conformational Constraint of an ADP Analog
J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 1038 - 1043.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
A. K. Filippov, J. M. Fernandez-Fernandez, S. J. Marsh, J. Simon, E. A. Barnard, and D. A. Brown
Activation and Inhibition of Neuronal G Protein-Gated Inwardly Rectifying K+ Channels by P2Y Nucleotide Receptors
Mol. Pharmacol., September 1, 2004; 66(3): 468 - 477.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics